Nortopixantrone, formerly known as BBR-3438, is a DNA topoisomerase inhibitor potentially for thetreatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). The antitumour efficacy of BBR 3438 against prostatic carcinoma could be the result of a combination of favourable events, including enhanced intracellular accumulation and an increased DNA-binding affinity favouring the accumulation of multiple sublethal or lethal damage. References: Hofheinz RD, Porta C, Hartung G, Santoro A, Hanauske AR, Kutz K, Stern A, Barbieri P, Verdi E, Hehlmann R, Hochhaus A. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Invest New Drugs. 2005 Aug;23(4):363-8. PubMed PMID: 16012796.

纯度：≥98%

CAS：438244-41-8